Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma
出版年份 2020 全文链接
标题
Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma
作者
关键词
-
出版物
Cancers
Volume 12, Issue 4, Pages 931
出版商
MDPI AG
发表日期
2020-04-10
DOI
10.3390/cancers12040931
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial
- (2020) Reinhard Dummer et al. LANCET ONCOLOGY
- Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients
- (2020) Victoria Atkinson et al. MELANOMA RESEARCH
- The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: Prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer
- (2019) Manvi Sharma et al. CANCER
- Pharmacokinetic and cytokine profiles of melanoma patients with dabrafenib and trametinib-induced pyrexia
- (2019) Hannah Yejin Kim et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Clinical Pharmacokinetic and Pharmacodynamic Considerations in the (Modern) Treatment of Melanoma
- (2019) Hannah Yejin Kim et al. CLINICAL PHARMACOKINETICS
- Impact of Concomitant Administration of Gastric Acid–Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials
- (2019) Olivier Mir et al. CLINICAL CANCER RESEARCH
- Quantitative Interrogation of the Human Kinome Perturbed by Two BRAF Inhibitors
- (2019) Weili Miao et al. JOURNAL OF PROTEOME RESEARCH
- Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
- (2019) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting Oncogenic BRAF: Past, Present, and Future
- (2019) Zaman et al. Cancers
- Relationship between vemurafenib plasma concentrations and survival outcomes in patients with advanced melanoma
- (2019) Ganessan Kichenadasse et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Clinical Pharmacokinetics and Pharmacodynamics of Dabrafenib
- (2018) Alicja Puszkiel et al. CLINICAL PHARMACOKINETICS
- Targeting oncogenic Raf protein-serine/threonine kinases in human cancers
- (2018) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600–Mutated Metastatic Melanoma
- (2018) Axel Hauschild et al. JAMA Oncology
- The safety and efficacy of dabrafenib and trametinib for the treatment of melanoma
- (2017) Sarah Knispel et al. Expert Opinion On Drug Safety
- Population pharmacokinetics and exposure–response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma
- (2016) Daniele Ouellet et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Plasma vemurafenib exposure and pre-treatment hepatocyte growth factor level are two factors contributing to the early peripheral lymphocytes depletion in BRAF-mutated melanoma patients
- (2016) Alicja Puszkiel et al. PHARMACOLOGICAL RESEARCH
- Clinical and kinomic analysis identifies peripheral blood mononuclear cells as a potential pharmacodynamic biomarker in metastatic renal cell carcinoma patients treated with sunitinib
- (2016) Gaёlle Noé et al. Oncotarget
- Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance
- (2015) E. Funck-Brentano et al. ANNALS OF ONCOLOGY
- Gastric Acid Suppression Is Associated With Decreased Erlotinib Efficacy in Non–Small-Cell Lung Cancer
- (2015) Michael P. Chu et al. Clinical Lung Cancer
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma
- (2015) N. Kramkimel et al. Targeted Oncology
- Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial
- (2014) A. M. Menzies et al. ANNALS OF ONCOLOGY
- Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF Inhibitor Dabrafenib (GSK2118436)
- (2014) G. S. Falchook et al. CLINICAL CANCER RESEARCH
- Molecular Pathways: Adaptive Kinome Reprogramming in Response to Targeted Inhibition of the BRAF-MEK-ERK Pathway in Cancer
- (2014) G. L. Johnson et al. CLINICAL CANCER RESEARCH
- Population pharmacokinetics of dabrafenib, a BRAF inhibitor: Effect of dose, time, covariates, and relationship with its metabolites
- (2014) Daniele Ouellet et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With MetastaticBRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor
- (2012) Kevin B. Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation